RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Yantai Yuhuangding Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorYantai Yuhuangding Hospital烟台毓璜顶医院YantaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07815223, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Have histologically or cytologically confirmed small-cell lung cancer;

    Inclusion criterion 4

  3. Have achieved a complete response, partial response, or stable disease after concurrent or sequential chemoradiotherapy, according to RECIST version 1.1;

    Inclusion criterion 6

  4. Have an ECOG performance status of 0 or 1;

    Inclusion criterion 3

  5. Received systemic immunostimulatory agents, including interferons, interleukin 2, or tumour necrosis factor, within 4 weeks or five half-lives before the first dose of study treatment, whichever is longer; previous cancer vaccines are permitted;

    Exclusion criterion 1

    Received any traditional Chinese herbal medicine for cancer control within 14 days before the first dose;

    Exclusion criterion 2

    Have had another active malignancy within 2 years before the first dose, except the cancer under investigation or definitively treated localised cancers, including resected basal-cell or squamous-cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast;

    Exclusion criterion 12

    Have untreated chronic hepatitis B, chronic HBV infection with an HBV DNA concentration of at least 500 IU/mL (2500 copies/mL), or active hepatitis C;

    Exclusion criterion 13

    Have a known history of HIV infection;

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07815223, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Provide written informed consent and be willing and able to comply with study requirements and scheduled assessments;
  • Be aged 18-75 years at the time of consent;
  • Have an ECOG performance status of 0 or 1;
  • Have histologically or cytologically confirmed small-cell lung cancer;
  • Have radiologically confirmed limited-stage disease;
  • Have achieved a complete response, partial response, or stable disease after concurrent or sequential chemoradiotherapy, according to RECIST version 1.1;
  • Have a life expectancy of at least 3 months;
  • Have adequate organ function.

Exclusion Criteria:

  • Received systemic immunostimulatory agents, including interferons, interleukin 2, or tumour necrosis factor, within 4 weeks or five half-lives before the first dose of study treatment, whichever is longer; previous cancer vaccines are permitted;
  • Received any traditional Chinese herbal medicine for cancer control within 14 days before the first dose;
  • Required systemic corticosteroids equivalent to more than 10 mg per day of prednisone or other immunosuppressive treatment within 14 days before the first dose;
  • Received a live vaccine within 4 weeks before the first dose; inactivated seasonal influenza vaccines are permitted, but live intranasal influenza vaccines are not;
  • Underwent major surgery requiring general anaesthesia within 28 days before the first dose;
  • Had previous allogeneic stem-cell or organ transplantation;
  • Have clinically significant pericardial effusion;
  • Have uncontrolled pleural effusion or ascites requiring drainage within 2 weeks before enrolment;
  • Have active autoimmune disease or a history of autoimmune disease with a risk of recurrence;
  • Have a history of interstitial lung disease or non-infectious pneumonitis, or uncontrolled systemic disease, including diabetes, hypertension, pulmonary fibrosis, or acute lung disease;
  • Have a severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral treatment within 2 weeks before the first dose, including tuberculosis;
  • Have had another active malignancy within 2 years before the first dose, except the cancer under investigation or definitively treated localised cancers, including resected basal-cell or squamous-cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast;
  • Have untreated chronic hepatitis B, chronic HBV infection with an HBV DNA concentration of at least 500 IU/mL (2500 copies/mL), or active hepatitis C;
  • Have a known history of HIV infection;
  • Have clinically significant cardiovascular risk factors;
  • Have unresolved toxicities from previous anticancer treatment that have not returned to baseline or stabilised, except adverse events unlikely to pose a safety risk, such as alopecia, neuropathy, or specified laboratory abnormalities;
  • Have a history of severe hypersensitivity to monoclonal antibodies.

Quoted from ClinicalTrials.gov, NCT07815223, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07815223, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07815223